Shockwave Medical (NASDAQ:SWAV) released its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.02, Bloomberg Earnings reports. The firm had revenue of $14.31 million during the quarter, compared to analysts’ expectations of $13.34 million. Shockwave Medical updated its FY 2020
After-Hours guidance to EPS.

Shares of SWAV traded down $3.39 during trading hours on Friday, reaching $44.35. 1,393,600 shares of the company traded hands, compared to its average volume of 379,907. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.76 and a quick ratio of 6.28. Shockwave Medical has a 12-month low of $24.58 and a 12-month high of $68.39. The business has a fifty day moving average price of $44.17 and a 200-day moving average price of $39.31.

In other news, major shareholder Sofinnova Capital Vii Fcpr sold 169,450 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $43.99, for a total transaction of $7,454,105.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Isaac Zacharias sold 4,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $40.24, for a total transaction of $160,960.00. Following the sale, the insider now directly owns 9,000 shares in the company, valued at $362,160. The disclosure for this sale can be found here. Insiders have sold 542,000 shares of company stock worth $23,600,976 over the last three months.

SWAV has been the topic of several analyst reports. Piper Sandler reaffirmed a “buy” rating and issued a $48.00 price target on shares of Shockwave Medical in a report on Thursday, January 23rd. Morgan Stanley lifted their price target on shares of Shockwave Medical from $35.00 to $47.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Canaccord Genuity cut their price target on shares of Shockwave Medical from $65.00 to $49.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Zacks Investment Research lowered shares of Shockwave Medical from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Oppenheimer initiated coverage on shares of Shockwave Medical in a report on Tuesday, October 22nd. They issued a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $47.17.

Shockwave Medical Company Profile

ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Featured Story: Limitations of the P/E Growth ratio

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.